60 results about "Appetite suppressing" patented technology

The invention discloses weight losing meal-replacing powder. The weight losing meal-replacing powder consists of the following components in part by weight: 15 to 50 parts of protein substance, 20 to 60 parts of functional sugar, 13 to 30 parts of water-soluble grain dietary fiber, 1 to 20 parts of water-soluble fruit dietary fiber, 2 to 30 parts of water-soluble vegetable dietary fiber, 0.05 to 0.18 part of vitamin bag, 5 to 20 parts of mineral bag and 0.1 to 0.5 part of spice. The meal-replacing powder is a special product developed for obese people who are usually busy in life, take less exercise and have irregular diet. After being taken, the meal-replacing powder produces strong satiety, inhibits appetite, does not cause malnutrition, has smooth mouthfeel, and can replace lunch or supper.

This invention relates to a nutritional intervention composition for enhancing satiety prior to a meal and extending satiety after a meal. The nutritional intervention composition decreases food intake producing weight loss over time. The composition consists of Niacin, Vitamin B6, Calcium, Phosphorous, Magnesium, Chromium, Chitosan, Fenugreek, Ginseng, White willow bark, Garcinia cambogia, Aloe Vera gel powder, Momordica charantia, Griffonia simplicifolia, Lagerstroemia speciosa and Vanadyl sulfate. The invention does not require stimulants or anabolic ingredients. There are three phases of activity within the composition. One, enhanced satiety through elevated serotonin. Two, improved carbohydrate metabolism, reduced blood glucose and slowed gastric emptying. Three, enhanced fiber binding of lipids and excess bile acids.

This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

A method to decrease feed intake in humans by ingesting a diet bar comprising of whole soybean and medium chain triglycerides and / or medium chain fatty acids, said bar containing an adequate level of nutrients to serve as a meal.

Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and / or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.

Disclosed is a method and device for treating obesity by suppressing appetite and hunger for periods of time when a person is wearing the vibration motor device. The vibration device having one or more vibrating motor unit(s), a battery holder for each vibrating motor unit, a power source (e.g., a battery) for operating the vibrating motor unit, optional resistor(s) an on / off switch and a necklace to suspend the vibrating device positioned over the stomach on the surface of the skin

Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and / or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass / lean mass ratio in a mammal (e.g. human).

An appetite suppressant toothpaste formulations which simultaneously suppresses the users appetite while promoting intraoral cleanliness. The toothpaste composition includes toothpaste base ingredients; and at least one of appetite suppressant and appetite depressant herbs. The toothpaste base ingredients include a combination of known amounts of Vegetable Glycerin; Sorbitol, Hydrated Silica; Purified Water; Xylitol; Carrageenan; Sodium Lauryl Sulfate; and Titanium Dioxide and a flavoring agent. The appetite suppressing and depressing herbs include at least one of Garcinia Cambogia; Gymnema Sylvestre; Kola Nut; Citrus Aurantium; Yerba Mate; and Griffonia Simplicifolia and comprise a range of substantially 5.5% to substantially 22% by weight of the composition. The appetite suppressing and depressing herbs may further include at least one of Guarana, Green Tea, myrrh, guggul Lipid and black current seed oil. Alternatively, the toothpaste composition may be in the form of a dental cream or mouthspray.

An appetite suppressant mouth spray formulation which simultaneously suppresses the user's appetite while promoting intraoral health. The mouth spray composition includes mouth spray base ingredients; and a plurality of appetite suppressant and appetite depressant herbs. The mouth spray base ingredients include a combination of Water; Glycerin; Xylitol; Propylene Glycol; Sodium Benzoate, Wintergreen Oil and a flavoring agent. A plurality of appetite suppressing and depressing herbs selected from the group consisting of Griffonia Simplicofolia; Garcina Cambogia; Kola Nut; Guarana; Yerba Mate; Myrrh Gum; Citrus Aurantium; Gymnema Sylvestre and Green Tea.

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.

Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

The present invention features a composition and method for suppressing appetite. The composition of the invention is composed of yerbe maté extract, guarana extract, and damiana extract in combination with a dietary fiber.

The present invention is double-maltol vanadium complex granule and capsule as diabetes treating medicine and their application. The medicine contains double-maltol vanadium complex as active component, and in the active complex double-maltol chelates vanadium to form five-element unsaturated vanadium-containing ring and vanadium is made to coordinate with oxygen, sulphur or nitrogen, preferablyoxygen. The medicine granule and capsule contains the active component as well as medicinal allowable supplementary material. The present invention is the development and extension of US patent No.5300496. The compound in the effective amount may be used in lower blood sugar and blood circulation as well as in inhibiting appetite for obesity and regulating cholesterol and triglyceride. The granule and the capsule with loose structure may be dissolved, diffused and absorbed to act.

A method for making the potassium, sodium and other hygroscopic salts of (−)-hydroxycitric acid and mixtures thereof workable by initial treatment with a desiccating agent, such as fumed silicon dioxide. These may be further rendered non-hygroscopic and non-reactive in acidic media via subsequent encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (−)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.

The present invention provides for compositions and related methods using extracts from the Cissus quadrangularis plant to improve and eliminate various cardiovascular risk factors and metabolic risk factors that cause Syndrome X. Controlled university studies demonstrated that 300 mg Cissus quadrangularis plant extract provided to obese humans daily for six weeks was effective to provide numerous health benefits including weight loss, improving the bodies fat burning mechanisms, increasing serum serotonin levels which causes appetite suppression and prevents binge eating and / or emotional eating, reducing total cholesterol, LDL cholesterol, triglyceride levels, fasting blood sugar levels and blood pressure, and increasing HDL or “good” cholesterol levels. Additional university controlled experiments also showed that extracts from the Cissus quadrangularis plant were effective in increasing lipase inhibition, α-amylase inhibition, α-glucosidase inhibition in rodents and that large doses of Cissus quadrangularis plant extracts were not toxic to rodents.

This disclosure relates to formulations and methods of suppressing appetite and eliciting satiety (sense of being filled) in mammals through the oral administration of an effective amount of an appetite suppressing moiety.

The invention belongs to the technical field of food processing, and particularly relates to health care oatmeal with a function of loosing weight, and a preparation method of the health care oatmeal. The health care oatmeal is prepared by the following raw materials: oatmeal, Chinese wampee fruits, rhodomyrtus tomentosa, mulberries, lotus leaves, herba lycopi and xylitol. The health care oatmeal with the function of loosing weight is prepared by combining the effective extraction components of natural fruits and plant extract components with effect of homology of medicine and food, thus having the effects of loosing weight, lubricating the intestines, relaxing the bowels, helping digestion, inhibiting appetite, removing fat and reducing blood pressure, balancing nutrition, beautifying and protecting skin, and the like; the health care oatmeal also has the characteristics that the raw materials are easily available, the operation is simple, the flavor is unique, the taste is good, the taking is convenient, etc.

The invention relates to appetite-suppressing compositions obtained from botanical sources. More specifically, the invention relates to appetite-suppressing compositions comprising an extract product of an Asclepias plant, methods of making an appetite-suppressing composition, and methods of suppressing an appetite.

The invention provides bread containing abundant chitin which accounts for 5-8% of the total weight of the bread. The weight-losing effect of the chitin is as follows: carboniums in the chitin is automatically attached to electronegative fat in food so as to block off the action of lipase so that the fat is not absorbed in intestine and is directly discharged out of body, wherein, the chitin is bonded with the fat and then is discharged out of body but is not bonded with protein in important nutrients, thus preventing harm on human body. Therefore, the bread containing the abundant chitin can be eaten securely by a person wanting to reduce weight without affecting nutrient absorption; and in addition, the chitin is different from the common diet food which reaches the weight-losing effect by suppressing appetite or causing diarrhea of the person, moreover, the chitin has the efficacy of improving a metabolism function of digestive tract.

Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants, mood enhancers and adjunctive therapy for arthritis, sleep apnea, fibromyalgia, diabetes and hyperglycemia. Additional chemical compounds of the present invention may include benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides, which may serve as precursors to phenolic compounds. The phenolic compounds and precursors of phenolic compounds of the present invention, at concentrations suitable for human therapeutic use, may be obtained from monocotyledonous plants such as corn in their early growth states which are timely harvested for optimum yield.

Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.

Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and / or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-erythro-2-(N-myristoylamino)-1- phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass / lean mass ratio in a mammal (e.g. human).

A chocolate based composition and method of promoting weight loss by suppressing appetite, inducing a feeling of satiety, and reducing ones craving for sweets and other food products while not adversely affecting the appearance, taste, texture, or scent of the chocolate. The composition comprises chocolate in combination with at least one or more of the following ingredients derived from the plant: Achyranthes (e.g., Achyranthes Aspera), Irvingia gabonensis, and Adansonia digitata Lin (e.g. Baobab). The composition is delivered orally in formulations suitable for drinking or eating comprising solid, powder, liquid, and combinations thereof.

The invention discloses the bioactive nanoparticles composed of chitosan, poly-glutamic acid, and at least one appetite-suppressing agent characterized with a positive surface charge and a method of treating obesity in a subject in need via their enhanced permeability in oral drug delivery.

The invention relates to a composition with a weight losing effect, and a preparation method and an application thereof. The composition with the weight losing effect comprises a green tea extract, L-carnitine and a coffee extract. According to the composition with the weight losing effect, the effects of reducing body fat, reducing weight and resisting fatigue are achieved in the aspects of inhibiting appetite, promoting lipolysis and transformation, improving the metabolism level of a human body and the like. The composition has a certain effect on obesity caused by various reasons, and hasa remarkable effect on overnutrition type obesity. The composition with the weight losing effect is free of transgenosis, soybeans, dairy products and gluten, belongs to 100% pure vegetarian food, isprepared from safe raw materials, and does not have any toxic or side effect on a human body.

The invention provides a propolis composition for reducing blood sugar and a preparation method thereof, and relates to the technical field of bee products. The propolis composition for reducing bloodsugar comprises the following raw materials in parts by weight: 80-120 parts of propolis, 20-50 parts of queen bee larva, 20-50 parts of royal jelly, 40-60 parts of dragon's blood extract, 20-50 parts of hawthorn extract, 30-50 parts of peach kernel extract, 30-60 parts of rhubarb extract and 20-50 parts of cassia twig extract. The invention has the advantage that rich and comprehensive nutritionis provided through the queen bee larva, the royal jelly and the propolis; a large amount of antioxidant enzymes and active ingredients are used for removing free radicals in cells; the sensitivity of cells to insulin receptors is improved, and the metabolism balance is kept; the dragon's blood extract and the hawthorn extract are used for stimulating various tissue cells to use glucose and lipidfor achieving the effects of reducing fat, lowering lipid and lowering blood sugar concentration, the peach kernel extract, the rhubarb extract and the cassia twig extract are used for inhibiting appetite and reducing excessive intake, a good blood sugar lowering effect is achieved, and no side effect is caused.